Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01745354 · ClinicalTrials.gov registry record · Phase 1
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase 1 study, sponsored by Robert Lowsky.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01745354 is a Phase 1 study that was terminated before completion, run by Robert Lowsky. The registered enrollment target is 6 participants.
The verdict
NCT01745354, a Phase 1 study, was terminated before completion, sponsored by Robert Lowsky.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
For patients with lymphoma that recurs after chemotherapy, bone marrow transplantation using cells from a healthy donor represents potentially curative treatment. In these individuals, cure is possible because transplantation of healthy donor immune cells can fight the lymphoma in the patient. The goal of this work is to test a strategy that activates the healthy donor immune cells so that they more effectively fight lymphoma and can result in an increased cure rate for these patients. Our group has previously studied CpG, an immune activating medication, in patients with lymphoma and demonstrated modest anti-tumor responses. We now have a more potent form of CpG which we intend to test to see if it will better activate the donor immune cells and result in shrinkage of tumor throughout the entire body, not just at the injected site.
Interventions
- DRUG SD-101
- RADIATION Local Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01745354
The ClinicalTrials.gov registry entry for NCT01745354 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robert Lowsky, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SD-101 is the first listed.
NCT01745354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01745354 about?
NCT01745354 is a clinical study titled "Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)". For patients with lymphoma that recurs after chemotherapy, bone marrow transplantation using cells from a healthy donor represents potentially curative treatment. In these individuals, cure is possible because transplantation of healthy donor immune cells can fight the lymphoma in the patient. The g...
What is the current status of trial NCT01745354?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-08. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01745354?
The interventions under investigation include: SD-101 (DRUG), Local Radiation (RADIATION).
Who is sponsoring clinical trial NCT01745354?
This trial is sponsored by Robert Lowsky, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.